APA (7. basım) Alıntı

Bradbury, L., Barlow, S., Geoghegan, F., Hannon, R., Stuckey, S., Wass, J., . . . Duncan, E. (2012). Risedronate in adults with osteogenesis imperfecta type I: Increased bone mineral density and decreased bone turnover, but high fracture rate persists.

Chicago Style (17. basım) Atıf

Bradbury, L., S. Barlow, F. Geoghegan, R. Hannon, S. Stuckey, J. Wass, R. Russell, M. Brown, ve E. Duncan. Risedronate in Adults with Osteogenesis Imperfecta Type I: Increased Bone Mineral Density and Decreased Bone Turnover, but High Fracture Rate Persists. 2012.

MLA (9th ed.) Atıf

Bradbury, L., et al. Risedronate in Adults with Osteogenesis Imperfecta Type I: Increased Bone Mineral Density and Decreased Bone Turnover, but High Fracture Rate Persists. 2012.